PE20151867A1 - Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados - Google Patents
Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizadosInfo
- Publication number
- PE20151867A1 PE20151867A1 PE2015002278A PE2015002278A PE20151867A1 PE 20151867 A1 PE20151867 A1 PE 20151867A1 PE 2015002278 A PE2015002278 A PE 2015002278A PE 2015002278 A PE2015002278 A PE 2015002278A PE 20151867 A1 PE20151867 A1 PE 20151867A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptides
- rsv
- prefusion
- soluble
- respiratory syncitial
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA INVENCION SE REFIERE A POLIPEPTIDOS F DE PREFUSION DEL VIRUS SINCICIAL RESPIRATORIO (RSV) ESTABLES, COMPOSICIONES INMUNOGENICAS QUE COMPRENDEN DICHOS POLIPEPTIDOS Y SUS USOS EN LA PREVENCION Y/O EL TRATAMIENTO DE UNA INFECCION POR RSV
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13165402 | 2013-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151867A1 true PE20151867A1 (es) | 2016-01-07 |
Family
ID=48326107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002278A PE20151867A1 (es) | 2013-04-25 | 2014-04-24 | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados |
Country Status (33)
Country | Link |
---|---|
US (3) | US10899800B2 (es) |
EP (2) | EP2988780B1 (es) |
JP (1) | JP6469081B2 (es) |
KR (1) | KR102236497B1 (es) |
CN (2) | CN110590916A (es) |
AP (1) | AP2015008815A0 (es) |
AR (1) | AR096113A1 (es) |
AU (1) | AU2014259474B2 (es) |
CA (1) | CA2910067C (es) |
CL (1) | CL2015003124A1 (es) |
CY (1) | CY1121600T1 (es) |
DK (1) | DK2988780T3 (es) |
EA (2) | EA039803B1 (es) |
ES (1) | ES2715378T3 (es) |
HK (1) | HK1220124A1 (es) |
HR (1) | HRP20190175T1 (es) |
HU (1) | HUE041659T2 (es) |
IL (1) | IL242186B (es) |
LT (1) | LT2988780T (es) |
ME (1) | ME03442B (es) |
MX (1) | MX361774B (es) |
MY (2) | MY181066A (es) |
PE (1) | PE20151867A1 (es) |
PH (1) | PH12015502377B1 (es) |
PL (1) | PL2988780T3 (es) |
PT (1) | PT2988780T (es) |
RS (1) | RS58436B1 (es) |
SG (1) | SG11201508567XA (es) |
SI (1) | SI2988780T1 (es) |
TR (1) | TR201902513T4 (es) |
TW (1) | TWI663175B (es) |
WO (1) | WO2014174018A1 (es) |
ZA (1) | ZA201507912B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009333484B2 (en) | 2008-12-09 | 2014-12-11 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
RU2761631C2 (ru) | 2013-03-13 | 2021-12-13 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Белки rsv в предшествующей слиянию конформации и их применение |
TR201902513T4 (tr) * | 2013-04-25 | 2019-03-21 | Janssen Vaccines & Prevention Bv | Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri. |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
WO2016160166A1 (en) * | 2015-03-30 | 2016-10-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic rsv polypeptides |
EP3319633B1 (en) | 2015-07-07 | 2020-11-11 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
BR112017028449A2 (pt) * | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | polipeptídeos rsv f pré-fusão solúveis estabilizados |
US10538557B2 (en) | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
CN108697790B (zh) * | 2015-09-03 | 2022-02-18 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
CN108738312A (zh) | 2015-12-23 | 2018-11-02 | 辉瑞公司 | Rsv f蛋白突变体 |
EP3892273A3 (en) * | 2016-02-03 | 2021-12-22 | Janssen Sciences Ireland Unlimited Company | Combination products for the treatment of rsv |
CA3015570A1 (en) | 2016-03-29 | 2017-10-05 | Peter Kwong | Substitutions-modified prefusion rsv f proteins and their use |
KR102506895B1 (ko) * | 2016-04-05 | 2023-03-08 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
EA201892250A1 (ru) * | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
AU2017272504A1 (en) * | 2016-05-30 | 2018-11-29 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion RSV F proteins |
CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
RU2019130167A (ru) | 2017-04-04 | 2021-05-05 | Юниверсити Оф Вашингтон | Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение |
JP2020519663A (ja) * | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Rsv感染に対する防御免疫を誘導するための方法及び組成物 |
WO2019053109A1 (en) * | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
AU2019238171A1 (en) | 2018-03-19 | 2020-09-24 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
US20210401969A1 (en) * | 2018-10-29 | 2021-12-30 | Emory University | Rsv virus-like particles and methods of use thereof |
JOP20210106A1 (ar) | 2018-11-13 | 2023-01-30 | Janssen Vaccines And Prevention B V | بروتينات rsv f سابقة الاندماج مستقرة |
CN109851678A (zh) * | 2019-03-07 | 2019-06-07 | 苏州宇之波生物科技有限公司 | 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用 |
CA3140234A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
BR112021022087A2 (pt) | 2019-05-15 | 2021-12-28 | Janssen Vaccines & Prevention Bv | Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus |
CN114502572A (zh) | 2019-09-04 | 2022-05-13 | 华盛顿大学 | 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
CN111303245B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种抗合胞病毒膜融合抑制剂 |
AU2021250630A1 (en) | 2020-04-02 | 2022-10-20 | Janssen Vaccines & Prevention B.V. | Stabilized vaccine compositions |
IL299515A (en) | 2020-06-29 | 2023-02-01 | Janssen Vaccines & Prevention Bv | Immune combination against respiratory syncytial virus infection |
CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
CN114195867B (zh) * | 2021-12-15 | 2024-05-03 | 北京交通大学 | 一种rsv融合前f蛋白、表达质粒、细胞株和rsv疫苗组合物 |
WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2024067725A1 (zh) * | 2022-09-29 | 2024-04-04 | 北京百邑无忧科技发展有限公司 | 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
CN116785421B (zh) * | 2023-08-21 | 2024-01-09 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 一种牛呼吸道合胞体病毒的mRNA疫苗及其应用 |
CN117736278A (zh) * | 2023-12-25 | 2024-03-22 | 英诺特(唐山)生物技术有限公司 | 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法 |
CN117586357B (zh) * | 2024-01-19 | 2024-07-09 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
US6485958B2 (en) | 1996-07-01 | 2002-11-26 | Gencell Sa | Method for producing recombinant adenovirus |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスe1−相補性細胞系 |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
KR100991683B1 (ko) | 1998-02-17 | 2010-11-04 | 쉐링 코포레이션 | 바이러스 제제의 농축방법 |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
AU1729600A (en) | 1998-11-16 | 2000-06-05 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
ES2354578T3 (es) | 1999-05-17 | 2011-03-16 | Crucell Holland B.V. | Adenovirus recombinante humano de serotipo ad26. |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
AU4346101A (en) | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
CA2415688A1 (en) | 2000-05-08 | 2001-11-15 | Anand Rao | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
CA2469491A1 (en) | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
MXPA04006995A (es) | 2002-01-18 | 2005-07-13 | Schering Ag | Formulaciones estabilizadas de adenovirus. |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
IL164802A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
MXPA04008891A (es) | 2002-04-25 | 2004-11-26 | Crucell Holland Bv | Medios y metodos para la produccion de vectores de adenovirus. |
US20050196854A1 (en) | 2002-05-14 | 2005-09-08 | Konz John O.Jr. | Methods of adenovirus purification |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
CA2496918A1 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
PL2163260T3 (pl) | 2004-01-23 | 2017-12-29 | Msd Italia S.R.L. | Szympansie adenowirusowe nośniki szczepionek |
CN1922308A (zh) | 2004-02-23 | 2007-02-28 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
ATE412737T1 (de) | 2005-04-11 | 2008-11-15 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
EP2099486A2 (en) | 2006-11-30 | 2009-09-16 | Government Of The United States Of America, As Represented by the Secretary | Codon modified immunogenic compositions and methods of use |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
SG188813A1 (en) * | 2007-12-24 | 2013-04-30 | Id Biomedical Corp Quebec | Recombinant rsv antigens |
WO2010014975A2 (en) | 2008-08-01 | 2010-02-04 | Academia Sinica | Use of microrna signatures for assessing risk levels of neuroblastoma patients |
MX2011004292A (es) | 2008-11-03 | 2011-05-31 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales. |
CA3108979A1 (en) | 2009-02-02 | 2010-08-05 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
KR20120093811A (ko) | 2009-06-24 | 2012-08-23 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 백신 |
AU2010264688A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
HRP20220756T1 (hr) | 2009-07-15 | 2022-09-02 | Glaxosmithkline Biologicals S.A. | Proteinski pripravci rsv f i postupci za izradu istih |
EA023179B1 (ru) | 2009-08-13 | 2016-05-31 | Круселл Холланд Б.В. | Антитела против респираторного синцитиального вируса (pcb) и способы их применения |
CN102791852B (zh) | 2009-10-15 | 2014-05-07 | 克鲁塞尔荷兰公司 | 纯化腺病毒颗粒的方法 |
MX2012004221A (es) | 2009-10-15 | 2012-06-08 | Crucell Holland Bv | Proceso para purificacion de adenovirus de cultivos de alta densidad celular. |
WO2011050168A2 (en) * | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
EA023816B1 (ru) | 2010-02-15 | 2016-07-29 | Круселл Холланд Б.В. | СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26 |
NZ603488A (en) | 2010-07-09 | 2015-02-27 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
RS56748B1 (sr) | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Pre-fuzioni rsv f antigeni |
WO2013135615A1 (en) | 2012-03-12 | 2013-09-19 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
AU2013237424B2 (en) | 2012-03-22 | 2017-07-06 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
JP2013247240A (ja) | 2012-05-25 | 2013-12-09 | Gigaphoton Inc | レーザ装置 |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
RU2761631C2 (ru) | 2013-03-13 | 2021-12-13 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Белки rsv в предшествующей слиянию конформации и их применение |
CN105189547B (zh) | 2013-04-15 | 2020-01-17 | 扬森疫苗与预防公司 | 结合到rsv g蛋白的人类抗体 |
TR201902513T4 (tr) | 2013-04-25 | 2019-03-21 | Janssen Vaccines & Prevention Bv | Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri. |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
EA202091315A3 (ru) | 2013-08-05 | 2021-06-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела человека, связывающиеся с g-белком rsv |
CA2923352C (en) | 2013-09-19 | 2022-05-03 | Crucell Holland B.V. | Stable adenovirus formulations |
KR102506895B1 (ko) * | 2016-04-05 | 2023-03-08 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
-
2014
- 2014-04-24 TR TR2019/02513T patent/TR201902513T4/tr unknown
- 2014-04-24 CA CA2910067A patent/CA2910067C/en active Active
- 2014-04-24 ES ES14719022T patent/ES2715378T3/es active Active
- 2014-04-24 EP EP14719022.7A patent/EP2988780B1/en active Active
- 2014-04-24 AP AP2015008815A patent/AP2015008815A0/xx unknown
- 2014-04-24 MY MYPI2015703748A patent/MY181066A/en unknown
- 2014-04-24 PL PL14719022T patent/PL2988780T3/pl unknown
- 2014-04-24 CN CN201910911639.8A patent/CN110590916A/zh active Pending
- 2014-04-24 PE PE2015002278A patent/PE20151867A1/es unknown
- 2014-04-24 LT LTEP14719022.7T patent/LT2988780T/lt unknown
- 2014-04-24 MX MX2015014890A patent/MX361774B/es active IP Right Grant
- 2014-04-24 PT PT14719022T patent/PT2988780T/pt unknown
- 2014-04-24 HU HUE14719022A patent/HUE041659T2/hu unknown
- 2014-04-24 RS RS20190170A patent/RS58436B1/sr unknown
- 2014-04-24 EA EA202090675A patent/EA039803B1/ru unknown
- 2014-04-24 AU AU2014259474A patent/AU2014259474B2/en active Active
- 2014-04-24 ME MEP-2019-73A patent/ME03442B/me unknown
- 2014-04-24 KR KR1020157032796A patent/KR102236497B1/ko active IP Right Grant
- 2014-04-24 EA EA201592048A patent/EA035522B1/ru unknown
- 2014-04-24 JP JP2016509467A patent/JP6469081B2/ja active Active
- 2014-04-24 US US14/786,955 patent/US10899800B2/en active Active
- 2014-04-24 EP EP18205858.6A patent/EP3488864A1/en active Pending
- 2014-04-24 CN CN201480023229.5A patent/CN105188745B/zh active Active
- 2014-04-24 WO PCT/EP2014/058353 patent/WO2014174018A1/en active Application Filing
- 2014-04-24 SG SG11201508567XA patent/SG11201508567XA/en unknown
- 2014-04-24 SI SI201431056T patent/SI2988780T1/sl unknown
- 2014-04-24 DK DK14719022.7T patent/DK2988780T3/en active
- 2014-04-25 TW TW103115087A patent/TWI663175B/zh active
- 2014-04-25 AR ARP140101738A patent/AR096113A1/es unknown
-
2015
- 2015-10-13 PH PH12015502377A patent/PH12015502377B1/en unknown
- 2015-10-20 IL IL242186A patent/IL242186B/en active IP Right Grant
- 2015-10-22 CL CL2015003124A patent/CL2015003124A1/es unknown
- 2015-10-23 ZA ZA2015/07912A patent/ZA201507912B/en unknown
-
2016
- 2016-07-13 HK HK16108218.1A patent/HK1220124A1/zh unknown
-
2018
- 2018-11-29 MY MYPI2018002243A patent/MY201791A/en unknown
-
2019
- 2019-01-28 HR HRP20190175TT patent/HRP20190175T1/hr unknown
- 2019-03-13 CY CY20191100303T patent/CY1121600T1/el unknown
-
2020
- 2020-12-18 US US17/126,128 patent/US20210101940A1/en not_active Abandoned
-
2022
- 2022-08-23 US US17/821,694 patent/US20230265127A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151867A1 (es) | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados | |
PH12015502735A1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
CL2017003151A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas | |
CL2017002709A1 (es) | Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr | |
BR112017028449A2 (pt) | polipeptídeos rsv f pré-fusão solúveis estabilizados | |
CL2015002335A1 (es) | Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas. | |
NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
PH12015501156A1 (en) | Pharmaceutical compositions | |
BR112017002370A2 (pt) | indóis para uso na infecção pelo vírus da gripe | |
NZ733125A (en) | Isoquinoline compounds for the treatment of hiv | |
IN2013MU01749A (es) | ||
CR20150648A (es) | Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido | |
CO2018007669A2 (es) | Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza | |
CL2017000714A1 (es) | Composiciones farmacéuticas de acción prolongada | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
CL2015003752A1 (es) | Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico | |
BR112015022134A2 (pt) | composto, composição farmacêutica, adesivo, bastão, dispensador de spray, tubo ou caneta, e, método de tratamento de uma infecção | |
CL2017001161A1 (es) | Composiciones farmacéuticas de acción prolongada para la hepatitis c | |
CL2017001160A1 (es) | Combinación de composiciones de acción prolongada y métodos para la hepatitis c | |
EA201890209A1 (ru) | Композиция, содержащая танины | |
MY169312A (en) | An antiviral pharmaceutical composition |